Watch the editorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2022 guidelines.
Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy.
Prof. Dr. Gontero is the Chair of the European guidelines for non-muscle-invasive bladder cancer (TaT1 and CIS).
Share this on your favourite network:
Reviewed by Mr. Hugh Mostafid (Royal Surrey County Hospital, Guildford, UK) UTUC: similarities and differences compared to bladder cancer While bladder tumours account for 90-95% of all urothelial carcinomas (UCa), only 5-10% of UCa cases involve the upper urinary...
Urinary biomarker tests, including Bladder EpiCheck®, are reimbursed from January 2024 in the Netherlands Reviewed by Prof. Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, The Netherlands) Pitfalls of the current standard for NMIBC follow-up Due to the high...
Henry, 70 years old, used to work as a creative director in a chocolate factory. Once, he designed chocolates that looked like broccoli. Too bad, they were not favoured by the clients … He was initially diagnosed with a solitary small Ta low-grade (LG) tumour. He...